Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
about
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesEpstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantInfluence of plasma exchange on rituximab pharmacokineticsThe impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification.Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.Active cytomegalovirus infection is not a risk factor for Epstein-Barr virus DNAemia in the allogeneic stem cell transplantation setting.Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
P2860
Q26745838-57F24EC5-AB22-43C0-8B18-94730750C93BQ26861623-3030B647-02D4-4B1C-8EF9-452B064F7100Q37161921-C408596E-D017-40F6-A81B-8907504E6E69Q40066662-E708D194-18CB-4589-8069-560333955F73Q40518920-3DEFA93F-4735-454C-B3A1-EBF4B2B85DF1Q40907778-996C6F48-568E-4D03-BD63-9B3991CC36D6Q41549338-FFDA9F91-DCEA-48F6-8AE7-6FF70FC0E752Q42209029-51C08524-D3E4-4B40-9DF3-E31AA6221B31Q42249125-F9EC6C55-32FD-4529-91E1-5F9FAA9FB692Q45347053-131D2EB1-28E2-483C-966A-27AD9A652031Q47587300-4F5543E2-9F50-403D-9AA3-5AA54BD630C8Q54379261-34037D92-95ED-4BAB-8D4F-433D359C69F3
P2860
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prognostic factors and outcome ...... ted with preemptive rituximab.
@en
Prognostic factors and outcome ...... ted with preemptive rituximab.
@nl
type
label
Prognostic factors and outcome ...... ted with preemptive rituximab.
@en
Prognostic factors and outcome ...... ted with preemptive rituximab.
@nl
prefLabel
Prognostic factors and outcome ...... ted with preemptive rituximab.
@en
Prognostic factors and outcome ...... ted with preemptive rituximab.
@nl
P2093
P2860
P356
P1476
Prognostic factors and outcome ...... ted with preemptive rituximab.
@en
P2093
A Michelutti
A Sperotto
C Savignano
E Toffoletti
F Patriarca
G Gregoraci
P2860
P304
P356
10.1111/TID.12061
P577
2013-02-13T00:00:00Z